News
-
-
PRESS RELEASE
EQS-Adhoc: Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025 due to internal system changes, extended reconciliation work, and audit delays -
-
-
-
-
-
PRESS RELEASE
Lotus Pharmaceutical becomes commercialization partner for Formycon's Keytruda® biosimilar candidate FYB206 across major parts of the Asia-Pacific Region
Lotus Pharmaceutical partners with Formycon AG for commercialization of Keytruda biosimilar FYB206 in Asia-Pacific region, marking a key step in Formycon's global strategy -
-
PRESS RELEASE
FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco® – Strengthening US Presence with Zydus as Commercialization Partner
FDA approves Formycon's Nufymco® as interchangeable Ranibizumab Biosimilar, partnering with Zydus for commercialization in the US, expanding access to retinal therapies
